SERPINA3 Antibody
- Known as:
- SERPINA3 Antibody
- Catalog number:
- GWB-MS364D
- Product Quantity:
- 50ug
- Category:
- -
- Supplier:
- GenWay
- Gene target:
- SERPINA3 Antibody
Related genes to: SERPINA3 Antibody
- Gene:
- SERPINA3 NIH gene
- Name:
- serpin family A member 3
- Previous symbol:
- AACT
- Synonyms:
- ACT
- Chromosome:
- 14q32.13
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2016-10-04
Related products to: SERPINA3 Antibody
Related articles to: SERPINA3 Antibody
- Ductal carcinoma in situ (DCIS) is a non-invasive precursor of invasive ductal carcinoma (IDC), yet the biological mechanisms underlying the transition from DCIS to IDC remain incompletely understood. Here, we integrate spatial transcriptomics, single-cell RNA sequencing, and single-cell DNA sequencing on coexisting DCIS and IDC samples to characterize cellular and microenvironmental alterations. Integrated analyses reveal differential molecular characterizations between coexisting DCIS and IDC and identify candidate genes (MGP, PLAT, and SERPINA3) potentially limiting the progression from DCIS to IDC. Malignant epithelial meta-programs (MPs) delineate distinct transcriptional states, with development-associated MP1 enriched in DCIS and cell cycle-related MP5 enriched in IDC. Further analysis reveals varied microenvironmental features in DCIS and IDC, with invasion-associated Mph_SPP1 and development-associated iCAFs_HOPX enriched in DCIS, while immunosuppressive Mph_PRDM1 and metabolism-related tCAFs_BNIP3 predominate in IDC. We then construct a machine learning model to identify DCIS at high risk of progression, which is externally validated across independent bulk RNA-sequencing cohorts (mean AUC = 0.903). Collectively, this study provides an integrative framework for understanding the molecular and spatial features that distinguish DCIS from IDC, with the potential to inform more precise risk stratification and clinical management for DCIS progression. - Source: PubMed
Publication date: 2026/09/27
Zhang NingWan TongZhang SiyueJiang YunzhenSu PengLiu JixinChen ZhitongHao JieWang HaoyuChen BingZhao WenjingWang LijuanXing TaoZhang QihuangSchmitz UlfDing ZhiyongCrosetto NicolaLiu BingqiangYang Qifeng - To examine the main adverse cardiovascular events that occur in individuals who have had an acute ST-segment elevation myocardial infarction (STEMI) after receiving percutaneous coronary intervention (PCI), such as serum C-type lectin domain family member 2 (CLEC2), serine protease inhibitor family member A3 (SERPINA3), and high-sensitivity C-reactive protein/albumin (hs-CRP/ALB) levels. - Source: PubMed
Ma YuncongFang SuxiaLiu ShashaJiang Zhencong - The molecular mechanisms linking vascular aging (VA) and heart failure (HF) remain elusive, hindering therapeutic strategies for their comorbidity. This study aimed to identify key biomarkers and pathways potentially involved in VA-HF synergy using integrative computational approaches. - Source: PubMed
Publication date: 2026/09/15
Li JinzeZhou GuitingWang QiaochuSong ZhixuanLiu JiantaoShen ChangzaoLuo ChuanjinWang Dawei - Rheumatoid Arthritis (RA) is a Prevalent Autoimmune Disorder Affecting Millions of People Worldwide. A Thorough Understanding of Its Clinical and Pathological Features Is Essential to Improve Patient Outcomes. - Source: PubMed
Zhao YangLi YuanQi MengXu JunhuaJi FengweiKan YanKong Chunyu - Cardiac fibrosis is a central driver of adverse remodeling and heart failure (HF), yet effective antifibrotic therapies remain limited. SerpinA3, a member of the serine protease inhibitor family, has been implicated in cardiovascular disease, but its functional role and underlying mechanisms in cardiac remodeling are poorly defined. - Source: PubMed
Publication date: 2026/08/30
Wang HuiCui JieyuHuang ChunluGuo WanyiLiu TongZhu YiShao ShuaiChen KangyinHe JinlongBao Qiankun